Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010115841 - METHODS AND MEANS FOR TREATMENT OF OSTEOARTHRITIS

Publication Number WO/2010/115841
Publication Date 14.10.2010
International Application No. PCT/EP2010/054412
International Filing Date 01.04.2010
IPC
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
CPC
A61P 19/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N 15/1137
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1137against enzymes
Applicants
  • Galapagos NV [BE]/[BE] (AllExceptUS)
  • BRYS, Reginald Christophe Xavier [BE]/[BE] (UsOnly)
  • NELLES, Luc [BE]/[BE] (UsOnly)
  • VANDEGHINSTE, Nick Ernest Rene [BE]/[BE] (UsOnly)
  • MILLE-BAKER, Blandine [FR]/[NL] (UsOnly)
  • TESSARI, Michela Angela [IT]/[NL] (UsOnly)
Inventors
  • BRYS, Reginald Christophe Xavier
  • NELLES, Luc
  • VANDEGHINSTE, Nick Ernest Rene
  • MILLE-BAKER, Blandine
  • TESSARI, Michela Angela
Agents
  • TEUTEN, Andrew
Priority Data
61/211,74001.04.2009US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND MEANS FOR TREATMENT OF OSTEOARTHRITIS
(FR) PROCÉDÉS ET MOYENS DE TRAITEMENT DE L'ARTHRITE
Abstract
(EN) The invention relates to the field of medicinal research, cartilage physiology and diseases involving the degeneration of cartilage tissue. More specifically, the invention relates to methods and means for identifying compounds that inhibit catabolic processes in chondrocytes and that decrease the degradation of cartilage and/or ECM. The invention also relates to the compounds that are useful in the treatment of osteoarthritis. The invention also relates to targets, the modulation of which results in a decrease in the degradation of ECM and/or cartilage and decrease inflammation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by the degradation of ECM and/or cartilage and inflammation.
(FR) La présente invention concerne le domaine de la recherche médicale, de la physiologie des cartilages et des maladies impliquant la dégénérescence du tissu cartilagineux. Plus spécifiquement, l'invention concerne des procédés et des moyens permettant d'identifier des composés qui inhibent les processus cataboliques dans les chondrocytes et qui diminuent la dégradation du cartilage et/ou de la matrice extracellulaire (ECM). L'invention concerne également les composés qui sont utiles dans le traitement de l'arthrose. L'invention concerne également des cibles dont la modulation aboutit à une diminution de la dégradation de l'ECM et/ou du cartilage et à une diminution de l'inflammation. De plus, l'invention concerne des compositions et des procédés destinés à être utilisés dans le traitement de troubles qui sont caractérisés par la dégradation de l'ECM et/ou du cartilage et par une inflammation.
Latest bibliographic data on file with the International Bureau